Form 4: Mineralys Therapeutics CFO Adam Levy Sells Shares Under 10b5-1 Trading Plan

Mineralys Therapeutics CFO Adam Levy sold 10,757 shares of common stock at a weighted-average price of $13.1444 per share under a pre-arranged 10b5-1 trading plan.

Summary

• On July 11, 2024, Adam Levy, CFO and Secretary of Mineralys Therapeutics, Inc., sold 10,757 shares of common stock.
• The sale was executed at a weighted-average price of $13.1444 per share, with individual transactions ranging from $12.93 to $13.43.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 14, 2023.
• Following the transaction, Levy directly owns 247,611 shares of Mineralys Therapeutics, Inc.
• This balance includes 2,906 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports a routine stock sale under a pre-arranged plan. The sale itself doesn't necessarily indicate a positive or negative outlook.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates the CFO's activity in the company's stock.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it influences the stock price, although the 10b5-1 plan mitigates concerns about insider information.

Key Dates